Literature DB >> 10025801

Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis.

A I Qureshi1, M A Choudhry, M S Akbar, Y Mohammad, H C Chua, A M Yahia, J A Ulatowski, D A Krendel, R T Leshner.   

Abstract

We performed a retrospective multicenter chart review to compare the efficacy and tolerance of plasma exchange (PE) and intravenous immunoglobulin (i.v.Ig) in treatment of 54 episodes of myasthenic crisis. After adjustment for other variables, PE (compared with i.v.Ig) was associated with a superior ventilatory status at 2 weeks (partial F = 6.2, p = 0.02) and 1 month functional outcome (partial F = 4.5, p = 0.04). However, the complication rate was higher with PE compared with i.v.Ig (13 versus 5 episodes, p = 0.07).

Mesh:

Substances:

Year:  1999        PMID: 10025801     DOI: 10.1212/wnl.52.3.629

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  29 in total

Review 1.  Treatment of myasthenia gravis.

Authors:  Vikas Kumar; Henry J Kaminski
Journal:  Curr Neurol Neurosci Rep       Date:  2011-02       Impact factor: 5.081

Review 2.  [Use of i.v. immunoglobulins in neurology. Evidence-based consensus].

Authors:  M Stangel; R Gold
Journal:  Nervenarzt       Date:  2004-08       Impact factor: 1.214

Review 3.  Myasthenic crisis.

Authors:  David Lacomis
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

4.  Myasthenia gravis: Five new things.

Authors:  Jeffrey M Statland; Emma Ciafaloni
Journal:  Neurol Clin Pract       Date:  2013-04

5.  Myasthenic crisis.

Authors:  Linda C Wendell; Joshua M Levine
Journal:  Neurohospitalist       Date:  2011-01

6.  Intravenous immunoglobulin for preparing myasthenia gravis patients for thymectomy and other surgical procedures preventing myasthenic crisis.

Authors:  J Gamez
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

Review 7.  Intravenous immunoglobulin in neurological disease: a specialist review.

Authors:  C M Wiles; P Brown; H Chapel; R Guerrini; R A C Hughes; T D Martin; P McCrone; J Newsom-Davis; J Palace; J H Rees; M R Rose; N Scolding; A D B Webster
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

8.  Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study.

Authors:  Chad Heatwole; Nicholas Johnson; Robert Holloway; Katia Noyes
Journal:  J Clin Neuromuscul Dis       Date:  2011-12

Review 9.  IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status.

Authors:  Isabel Illa
Journal:  J Neurol       Date:  2005-05       Impact factor: 4.849

10.  Myasthenic Crisis.

Authors:  Jawad F. Kirmani; Abutaher M. Yahia; Adnan I. Qureshi
Journal:  Curr Treat Options Neurol       Date:  2004-01       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.